IP Library › Granted Patent US 12,473,560
Granted Patent B2
US 12,473,560 · App. 18/151,088 · Granted Nov 18, 2025

Antigen binding molecules targeting SARS-CoV-2

Inventors: Gevorg Grigoryan (Arlington, MA); John Ingraham (Cambridge, MA); Cheuk Lun Leung (Quincy, MA); Ross Steven Federman (Dorchester, MA); Robin Jeffrey Green (Jamaica Plain, MA); Vincent Xue (Winchester, MA); Craig Owen MacKenzie (Bradford, VT)
Assignee: Flagship Pioneering Innovations VI, LLC
C12N15/63C07K16/1003C07K2317/565C07K2317/76C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,473,560
App. No.
18/151,088
Granted
Nov 18, 2025
Kind
B2
Abstract

The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).

Claims (18)

1 . An antibody or an antigen-binding fragment thereof that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike), comprising:

a) an immunoglobulin heavy chain variable region (V H ) comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are identical to SEQ ID NO: 18, SEQ ID NO: 21, and SEQ ID NO: 24, respectively; and

b) an immunoglobulin light chain variable region (V L ) comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2) and a light chain complementarity determining region 3 (LCDR3) that are identical to SEQ ID NO: 31, AAS, and SEQ ID NO: 36, respectively.

2 . The antibody or antigen-binding fragment thereof of claim 1 , wherein:

c) the V H comprises SEQ ID NO: 44; and

d) the V L comprises SEQ ID NO: 48.

3 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the V H and V L are humanized, contain human framework regions, or a combination thereof.

4 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the antigen binding fragment is selected from Fab, F(ab′) 2 , Fab′, scFv, or Fv.

5 . The antibody or antigen-binding fragment thereof of claim 1 , further comprising an antibody heavy chain constant region sequence, an antibody light chain constant region sequence, or both an antibody heavy chain constant region sequence and an antibody light chain constant region sequence.

6 . The antibody or antigen-binding fragment thereof of claim 5 , wherein the antibody heavy chain constant region is selected from the group consisting of an IgA constant region, an IgD constant region, an IgE constant region, an IgG constant region and an IgM constant region.

7 . The antibody or antigen-binding fragment thereof of claim 6 , wherein the antibody heavy chain constant region is an IgG1 heavy chain constant region.

8 . A fusion protein comprising the antibody or antigen-binding fragment thereof of claim 1 and a heterologous polypeptide.

9 . A polynucleotide comprising a nucleotide sequence encoding the antibody or antigen-binding fragment thereof of claim 1 .

10 . An expression vector comprising the polynucleotide of claim 9 .

11 . An isolated host cell comprising the polynucleotide of claim 9 .

12 . A composition comprising the antibody or antigen-binding fragment thereof of claim 1 and one or more pharmaceutical excipients, diluents, or carriers.

13 . A method of treating a SARS-COV-2 infection in a subject in need thereof, comprising administering an effective amount of the composition of claim 12 to the subject.

14 . A method of inhibiting fusion between SARS-CoV-2-Spike and a cell in a subject, comprising contacting the cell with an effective amount of the composition of claim 12 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2024
From: GRIGORYAN, GEVORG; INGRAHAM, JOHN; LUN LEUNG, CHEUK; FEDERMAN, ROSS STEVEN; GREEN, ROBIN JEFFREY; XUE, VINCENT; MACKENZIE, CRAIG OWEN
To: GENERATE BIOMEDICINES, INC.
Reel/Frame 066731/0582 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2024
From: GENERATE BIOMEDICINES, INC.
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 066731/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2024
From: FLAGSHIP PIONEERING, INC.
To: FLAGSHIP PIONEERING INNOVATIONS VI, LLC
Reel/Frame 066731/0599 →
Continuity (4)
Continuation PCTUS2021040533 · Jul 6, 2021
Provisional Application 63070038 · Aug 25, 2020
Provisional Application 63048588 · Jul 6, 2020
Related Publication 20230279081A1 · Sep 7, 2023
References Cited (360)
US 8088376B2 · Chamberlain et al. · 2012 [cited by applicant]
US 8394925B2 · Chamberlain et al. · 2013 [cited by applicant]
US 8546543B2 · Lazar · 2013 [cited by applicant]
US 9803023B2 · Chamberlain et al. · 2017 [cited by applicant]
US 10336818B2 · Chamberlain et al. · 2019 [cited by applicant]
US 10787501B1 · Babb et al. · 2020 [cited by applicant]
US 11028167B1 · Glanville et al. · 2021 [cited by applicant]
US 11168128B2 · Corti et al. · 2021 [cited by applicant]
US 11192940B2 · Walker et al. · 2021 [cited by applicant]
US 20150152183A1 · Chamberlain et al. · 2015 [cited by applicant]
US 20160046720A1 · Sato et al. · 2016 [cited by applicant]
US 20190119407A1 · Hsu et al. · 2019 [cited by applicant]
US 20210214431A1 · Rommelaere et al. · 2021 [cited by applicant]
US 20210261650A1 · Corti et al. · 2021 [cited by applicant]
US 20210277095A1 · Chamberlain et al. · 2021 [cited by applicant]
US 20220089752A1 · Liu et al. · 2022 [cited by applicant]
US 20220112307A1 · Chamberlain et al. · 2022 [cited by applicant]
US 20220403009A1 · Hinton et al. · 2022 [cited by applicant]
US 20230058162A1 · Hinton et al. · 2023 [cited by applicant]
US 20230174628A1 · Xie et al. · 2023 [cited by applicant]
US 20230287089A1 · Grigoryan et al. · 2023 [cited by applicant]
US 20230295275A1 · Grigoryan et al. · 2023 [cited by applicant]
US 20230357366A1 · Borriello et al. · 2023 [cited by applicant]
US 20230357367A1 · Borriello et al. · 2023 [cited by applicant]
EP 2235059B1 · 2015 [cited by applicant]
EP 2444423B1 · 2015 [cited by applicant]
EP 3031913A1 · 2016 [cited by applicant]
EP 2808343B1 · 2019 [cited by applicant]
EP 3872091A1 · 2021 [cited by applicant]
EP 3138853B1 · 2021 [cited by applicant]
EP 4147716A1 · 2023 [cited by applicant]
EP 4188951A2 · 2023 [cited by applicant]
WO 2005012360A2 · 2005 [cited by applicant]
WO 2005054469A1 · 2005 [cited by applicant]
WO 2006051091A1 · 2006 [cited by applicant]
WO 2006053301A2 · 2006 [cited by applicant]
WO 2009058492A2 · 2009 [cited by applicant]
WO 2009086320A1 · 2009 [cited by applicant]
WO 2016050889A1 · 2016 [cited by applicant]
WO 2021156490A2 · 2021 [cited by applicant]
WO 2021158521A1 · 2021 [cited by applicant]
WO 2021173753A1 · 2021 [cited by applicant]
WO 2021186190A1 · 2021 [cited by applicant]
WO 2021203053A1 · 2021 [cited by applicant]
WO 2021207152A1 · 2021 [cited by applicant]
WO 2021211775A1 · 2021 [cited by applicant]
WO 2021226560A1 · 2021 [cited by applicant]
WO 2021247925A1 · 2021 [cited by applicant]
WO 2022010912A1 · 2022 [cited by applicant]
WO 2022010921A1 · 2022 [cited by applicant]
WO 2022015573A2 · 2022 [cited by applicant]
WO 2022026475A2 · 2022 [cited by applicant]
WO 2022046888A1 · 2022 [cited by applicant]
WO 2022047033A1 · 2022 [cited by applicant]
WO 2022140845A1 · 2022 [cited by applicant]
WO 2022159685A2 · 2022 [cited by applicant]
WO 2022204202A1 · 2022 [cited by applicant]
WO 2022251119A2 · 2022 [cited by applicant]
WO 2022271863A1 · 2022 [cited by applicant]
WO 2023028603A2 · 2023 [cited by applicant]
WO 2023037119A1 · 2023 [cited by applicant]
WO 2023215910A1 · 2023 [cited by applicant]
Abbasi J., “Researchers Tie Severe Immunosuppression to Chronic COVID-19 and Virus Variants,” JAMA, vol. 325; No. 20; 2033-2035 (2021). [cited by applicant]
Agrawal U et al., Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, … [cited by applicant]
Al-Lazikani, B. et al., “Standard Conformations for the Canonical Structures of Immunoglobulins,” J. Mol. Biol., vol. 273; 927-948 (1997). [cited by applicant]
Almagro et al., “Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy” Front. Immunol., 8:1751, doi: 10.3389/fimmu.2017.01751 (2018). [cited by applicant]
Almagro, J.C., “Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires,” Journal of Mo… [cited by applicant]
Andreano, E. et al., “mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5,” bioRxiv, https://doi.org/10.1101/2022.08.04.502828; 31 pages (2022). [cited by applicant]
Aschner, C.B. et al., “A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo,” Sci. Transl. Med., vol. 15(697); eadf4549, 13 pages (2023). [cited by applicant]
Australian Government, “Australian Public Assessment Report for Sotrovimab,” Proprietary Product Name: Xevudy, Sponsor: GlaxoSmithKline Australia Pty Ltd; 58 pages (2021). [cited by applicant]
Baden, L.R. and Rubin, E.J., “Covid-19—The Search for Effective Therapy,” The New England Journal of Medicine, vol. 382; No. 19; 1851-1852 (2020). [cited by applicant]
Barnes CO et al., SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. Dec. 2020;588(7839):682-687. doi: 10.1038/s41586-020-2852-1. Epub Oct. 12, 2020. PMID: 33045718; PMCID: PMC8092461. [cited by applicant]
Bartsch, Y.C. et al., “Antibody effector functions are associated with protection from respiratory syncytial virus,” Cell, vol. 185; 4873-4886 (2022). [cited by applicant]
Bassetti M et al., Co-localization of secretogranins/chromogranins with thyrotropin and luteinizing hormone in secretory granules of cow anterior pituitary. J Histochem Cytochem. Sep. 1990;38(9):1353-63. doi: 10.1177/38… [cited by applicant]
Baud, D. et al., “Real estimates of mortality following COVID-19 infection,” Lancet Infect Dis., vol. 20; No. 7; 773 (2020). [cited by applicant]
Baum A. et al., “REGN-COV2 antibodies prevent and treat SARSCoV-2 infection in rhesus macaques and hamsters,” Science, vol. 370; No. 6520; 1110-1115 (2020). [cited by applicant]
Baum, A. et al., “Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies,” Science, vol. 369; 1014-1018 (2020). [cited by applicant]
Bedouelle et al. (FEBS J. Jan. 2006; 273(1):34-46). (Year: 2006). [cited by applicant]
Bender Ignacio RA et al., Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection. Clin Pharmacol Ther. Dec. 2022;112(6):120… [cited by applicant]
Boggiano, C. et al., “Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19,” Ann Intern Med, 9 pages (2021). [cited by applicant]
Böttcher E et al. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol. Oct. 2006; 80(19):9896-8. doi: 10.1128/JVI.01118-06. PMID: 16973594; PMCID: PMC161… [cited by applicant]
Bournazos S et al., Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. Sep. 11, 2014;158(6):1243-1253. doi: 10.1016/j.cell.2014.08.023. PMID: 25215485; PMCID: PMC4167398. [cited by applicant]
Brown et al. (J Immunol. May 1, 1996; 156(9):3285-91). (Year: 1996). [cited by applicant]
Bruel, T., “Evidence in support of the use of serum neutralisation data to justify a dose increase of monoclonal antibodies to tackle new variants,” EMA/FDA joint meeting, Institut Pasteur, Virus and Immunity Unit, Oliv… [cited by applicant]
Bulun, S.E., “Reproductive Physiology,” Physiology and Pathology of the Female Reproductive Axis, Chapter 17; pp. 590-663; Williams Textbook of Endocrinology, Fourteenth Edition (2020). [cited by applicant]
Burnett, D.L. et al., “Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability,” Immunity, vol. 54(12); 2908-2921 (2021). [cited by applicant]
Cao Z et al., VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med. Feb. 2, 2023;388(5):406-417. doi: 10.1056/NEJMoa2208822. Epub Dec. 28, 2022. PMID: 36577095; PMCID: PMC9812289. [cited by applicant]
Cao Z et al., VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med. Feb. 2, 2023;388(5):406-417. doi: 10.1056/NEJMoa2208822. Epub Dec. 28, 2022. PMID: 36577095; PMCID: PMC9812289; Supplementa… [cited by applicant]
Cao Z et al., VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med. Feb. 2, 2023;388(5):406-417. doi: 10.1056/NEJMoa2208822. Epub Dec. 28, 2022. PMID: 36577095; PMCID: PMC9812289; The Protoco… [cited by applicant]
Cao, Y. et al., “B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes,” bioRxiv, 30 pages (2021). [cited by applicant]
Cao, Y. et al., “BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection,” Nature, vol. 608(7923); 593-602 (2022). [cited by applicant]
Cao, Y. et al., “Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,” bioRxiv, 38 pages (2022). [cited by applicant]
Cao, Y. et al., “Omicron BA.2 specifically evades broad sarbecovirus neutralizing antibodies,” bioRxiv, 39 pages (2022). [cited by applicant]
Case JB et al., Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe. Sep. 9, 2020;28(3):475-485.e5. doi: 10.1016/j.chom.202… [cited by applicant]
Case JB et al., Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. Jul. 2, 2022;13(1):3824. doi: 10.1038/s41467-022-31615-7. PMID: 35780162… [cited by applicant]
Case, B., “Development of a Pan-Sarbecovirus Mucosal Vaccine,” Instructor in Medicine Washington University School of Medicine IDWeek: Next Generation COVID-19 Vaccines, Boston, MA, 16 pages (2023). [cited by applicant]
Cathcart A.L. et al., “The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2,” BioRxiv, https://doi.org/10.1101/2021.03.09.434607 (2022). [cited by applicant]
Center for Drug Evaluation and Research, Approval Package for: Application No. 761108Orig1s000, Trade Name: Ultomiris Injection, 300 mg / 30mL (10 mg / mL), retrieved from Internet URL: https://www.google.com/url?sa=t&r… [cited by applicant]
Centers for Disease Control and Prevention website. COVID-19 vaccines for people who are moderately or severely immunocompromised. Updated Jan. 31, 2023. Accessed Feb. 17, 2023. https://www.cdc.gov/coronavirus/2019-ncov… [cited by applicant]
Cerutti, G. et al., “Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARSCoV-2 neutralizing antibodies,” Structure, vol. 29(7); 655-663 (2021). [cited by applicant]
Chan, J.F. et al., “Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility,” Clin I… [cited by applicant]
Chan, K.K. et al., “Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2,” Science. Sep. 4, 2020;369(6508):1261-1265. doi: 10.1126/science.abc0870. Epub Aug. 4, 2020. PMID: 32753553; PMC… [cited by applicant]
Chen et al. “CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants”, Bioinformatics 38(6):1735-37 (2022). [cited by applicant]
Chen, P. et al., “First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19,” Clinical Pharmacology & Therapeutics, vol. 110; No. 6; 1467-1477 (2021). [cited by applicant]
Chigutsa, E. et al., “A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal Antibodies to Advance Bamlanivimab Into a First-in-Human Clinical Trial,” Clin… [cited by applicant]
Chigutsa, E. et al., “Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection,” Clinical Pharmacology & Therapeuti… [cited by applicant]
Choy, R.K.M. et al., “Controlled Human Infection Models To Accelerate Vaccine Development,” Clinical Microbiology Reviews, vol. 35; Issue 3; 163 pages (2022). [cited by applicant]
Colman (Research in Immunology, 145:33-36, 1994). (Year: 1994). [cited by applicant]
Copin, R. et al., “The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies,” Cell, vol. 184(15); 3949-3961 (2021). [cited by applicant]
Corbett, K.S. et al., “Immune Correlates of Protection by mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates,” Science, vol. 373; No. 6561; eabj0299; 23 pages (2021). [cited by applicant]
Correa Giron, C. et al., “On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2,” Virus Research, vol. 285; 198021; 13 pages (202… [cited by applicant]
Corti et al. “Tackling COVID-19 with neutralizing monoclonal antibodies”, Cell 184(12):3086-3108 (2021). [cited by applicant]
Crawford JL & McNeilly AS. Co-localisation of gonadotrophins and granins in gonadotrophs at different stages of the oestrous cycle in sheep. J Endocrinol. Aug. 2002;174(2):179-94. doi: 10.1677/joe.0.1740179. PMID: 12176… [cited by applicant]
Crawford KHD et al., Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses. May 6, 2020;12(5):513. doi: 10.3390/v12050513. PMID: 32384820; PMCID: PM… [cited by applicant]
Credle, J.J. et al., “Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries,” Nature Biomedical Engineering, vol. 6(8); 992-1003 (2022). [cited by applicant]
Cromer D et al., Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. Jan. 2022;3(1):e52-e61. doi: 10.1016/S2666-5247(21)00267… [cited by applicant]
Cuccarese, M.F. et al., “Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,” bioRxiv, 24 pages (2020). [cited by applicant]
Database, RCSB PDB [Online], “7NAB Crystal structure of human neutralizing mAb CV3-25 binding to SARS-CoV-2 S MPER peptide 1140-1165”, 5 pages, PDB DOI: https://doi.org/10.2210/pdb7NAB/pdb (2021). [cited by applicant]
Davenport, M., “Correlates of protection using a neutralisation approach,” Kirby Institute, 25 pages (2022). [cited by applicant]
Davis-Gardner, M.E. et al., “mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1,” bioRxiv; https://doi.org/10.1101/2022.10.31.514636; 7 pages (2022). [cited by applicant]
De Gasparo, R.D. et al., “Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice,” Nature, vol. 593(7859); 424-428 (2020). [cited by applicant]
De Genst et al., “Anti body repertoire development in camelids” Dev Comp Immunol; 30:187-98 (2006). [cited by applicant]
Dejnirattisai, W. et al., “The antigenic anatomy of SARS-CoV-2 receptor binding domain,” Cell, vol. 184; 2183-2200 (2021). [cited by applicant]
Dings C et al., Pharmacometric Modeling of the Impact of Azelastine Nasal Spray on SARS-CoV-2 Viral Load and Related Symptoms in COVID-19 Patients. Pharmaceutics. Sep. 27, 2022;14(10):2059. doi: 10.3390/pharmaceutics 14… [cited by applicant]
Divine, R. et al., “Designed proteins assemble antibodies into modular nanocages,” Science, vol. 372(6537); No. 47; 17 pages (2021). [cited by applicant]
Dougan, M. et al., “A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high vira… [cited by applicant]
Dougan, M. et al., “Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19,” medRxiv, 33 pages (2022). [cited by applicant]
Dube, S. et al., “Fully vaccinated individuals with immunocompromised conditions are still at increased risk of severe COVID-19 outcomes from the Omicron variant: initial results from Inform, a retrospective health data… [cited by applicant]
Durán-Pastén ML & Fiordelisio T. GnRH-Induced Ca(2+) Signaling Patterns and Gonadotropin Secretion in Pituitary Gonadotrophs. Functional Adaptations to Both Ordinary and Extraordinary Physiological Demands. Front Endocr… [cited by applicant]
Edara VV et al., Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. JAMA. May 11, 2021;325(18):1896-1898. doi: 10.1001/jama.2021.4388. PMID: 33739374; PMCID: PMC7980146. [cited by applicant]
EMA website. CHMP Assessment Report for Sotrovimab, Dec. 2021. Updated Jan. 12, 2023. Accessed May 22, 2023. https://www.ema.europa.eu/en/documents/assessmentreport/xevudy-epar-public-assessment-report_en.pdf. [cited by applicant]
Esparza, T.J. and Brody, D.L., “High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme,” bioRxiv, Retrieved from Internet URL: https://www.biorxiv.or… [cited by applicant]
European Cancer Patient Coalition (ECPC). Joint statement on the protection of immunocompromised patients during the COVID-19 pandemic. Updated Jul. 7, 2022. Accessed Feb. 17, 2023. https://ecpc.org/joint-statement-on-t… [cited by applicant]
European Medicines Agency, Assessment Report, Evusheld, 155 pages (2022). [cited by applicant]
European Medicines Agency, CHMP Assessment Report for Xevudy; 120 pages (2021). [cited by applicant]
Eyal, N. et al., “Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure,” The Journal of Infectious Diseases, vol. 221; 1752-1756 (2020). [cited by applicant]
Fact Sheet for Health Care Providers, Bamlanivimab and Etesevimab, Eli Lilly and Company, 45 pages (2021). [cited by applicant]
Fact Sheet for Health Care Providers, casirivimab and imdevimab, Regeneron Pharmaceuticals, Inc, 54 pages (2021). [cited by applicant]
Fact Sheet for Health Care Providers, Sotrovimab, GlaxoSmithKline LLC, 37 pages (2022). [cited by applicant]
FDA Briefing Document, “Bezlotoxumab Injection, Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC)” 29 pages (2016). [cited by applicant]
FDA Briefing Document, “Vaccines and Related Biological Products Advisory Committee Meeting,” EUA amendment request for use of the Moderna COVID-19 Vaccine in children 6 months through 17 years of age, 190 pages (2022). [cited by applicant]
Fedry, J. et al., “Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11,” Sci. Adv., vol. 7(23); eabf5632, 11 pages (2021). [cited by applicant]
Fenwick, C. et al., “A highly potent antibody effective against SARS-CoV-2 variants of concern,” Cell Reports, vol. 37(2); 109814; 19 pages (2021). [cited by applicant]
Fenwick, C. et al., “Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys,” Nature Microbiology, 33 pages (2022). [cited by applicant]
Follmann D et al., Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nat Commun. Jun. 17, 2023;14(1): 23 pages; Supplemental Materials. [cited by applicant]
Follmann D et al., Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nat Commun. Jun. 17, 2023;14(1):3605. doi: 10.1038/s41467-023-39292-w. PMID:… [cited by applicant]
Francica, J.R. et al., “The SARS-CoV-2 monoclonal antibody AZD3152 potently neutralises historical and currently circulating variants,” Presented at the European Congress of Clinical Microbiology and Infectious Diseases… [cited by applicant]
Francica, J.R. et al., “The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-Risk Individuals,” IDW… [cited by applicant]
Gau, B.C. et al., “Oligonucleotide mapping via mass spectrometry to enable comprehensive primary structure characterization of an mRNA vaccine against SARS-CoV-2,” Scientific Reports, vol. 13; 9038; 16 pages (2023). [cited by applicant]
Gauvreau, G.M. et al., “Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses,” N. Eng J Med, vol. 370; 2102-2110 (2014). [cited by applicant]
Genbank, “Lama glama immunoglobulin heavy chain variable region mRNA, partial eds,” Database accession No. MT350284; 2 Pages (2020). [cited by applicant]
Gilbert PB et al., Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. Jan. 7, 2022;375(6576): 75 pages; Supplemental Material. [cited by applicant]
Gilbert PB et al., Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. Jan. 7, 2022;375(6576):43-50. doi: 10.1126/science.abm3425. Epub Nov. 23, 2021. PMID: 34812653; PMCID: PM… [cited by applicant]
Gilbert, P.B. et al., “A Covid-19 Milestone Attained—A Correlate of Protection for Vaccines,” N Engl J Med, vol. 387; No. 24; 2203-2206 (2022). [cited by applicant]
Gobeil, S. et al., “Structural diversity of the SARS-CoV-2 Omicron spike,” bioRxiv; 35 pages (2022). [cited by applicant]
Gov.UK, “Winter Coronavirus (COVID-19) Infection Study: estimates of epidemiological characteristics, Dec. 21, 2023,” Retrieved from Internet URL: https://www.gov.uk/government/statistics/winter-coronavirus-covid-19-inf… [cited by applicant]
Greaney AJ et al., Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe. Jan. 13, 2021;29(1):44-57.e9. doi: 10.1016/j.chom.2020.11.007. Epub N… [cited by applicant]
Greaney, A.J. et al., “Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies,” bioRxiv, 35 pages (2021). [cited by applicant]
Gruell, H. et al., “Antibody-mediated neutralization of SARS-CoV-2,” Immunity, vol. 55(6); 925-944 (2022). [cited by applicant]
Gupta, A. et al., “Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab,” N Eng J Med, vol. 385(21); 1941-1950 (2021). [cited by applicant]
Gupta, A. et al., “Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab,” N Eng J Med, vol. 385(21); The Protocol; 269 pages (2021). [cited by applicant]
Gutgsell, A.R. et al., “Biosensor-Enabled Deconvolution of the Avidity-Induced Affinity Enhancement for the SARS-CoV-2 Spike Protein and ACE2 Interaction,” Anal Chem, vol. 94; 1187-1194 (2022). [cited by applicant]
Li, T. et al., “A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection,” Nature Communication, vol. 12; 4635; 13 pages (2021). [cited by applicant]
Liu Z et al., Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. Mar. 10, 2021;29(3):477-488.e4. doi: 10.1016/j.chom.2021.01.014. Epub Jan. 27, 2… [cited by applicant]
Liu, H. and Wilson, I.A., “Protective neutralizing epitopes in SARS-CoV-2,” Immunol Rev, vol. 310; No. 1; 76-92 (2022). [cited by applicant]
Liu, H. et al., “A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection,” Cell Host & Microbe, vol. 29; 806-818 (2021). [cited by applicant]
Liu, L. et al., “Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection,” JCI Insight, vol. 4; No. 4; e123158; 20 pages (2019). [cited by applicant]
Liu, L. et al., “Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking,” Immunity, vol. 56(10); 2442-2455 (2023). [cited by applicant]
Liu, L. et al., “Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike,” Nature, vol. 584; 450-456 (2020). [cited by applicant]
Loo, Y.M. et al., “The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans,” Sci. Transl. Med., vol. 14; No. 635; eabl8124; 15 Pages (2022). [cited by applicant]
Low, J.S. et al., “ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies,” bioRxiv, 56 pages (2022). [cited by applicant]
Mahoney, K. et al., “1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention,” Open Forum Infect Dis. Nov. 2… [cited by applicant]
Markovic, I. and Savvides, S., “Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer,” Frontiers in Immunology, vol. 11; Art. 1557; 19 pages (2020). [cited by applicant]
Martinez, D.R. et al., “A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice,” Sci. Transl. Med., 10.1126/scitranslmed.abj7125; Jan. 26, 2022; 14(629):eabj7125; 18 pages. [cited by applicant]
McCallum, M. et al., “Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement,” bioRxiv, 27 pages (2021). [cited by applicant]
McMahan, K. et al., “Correlates of protection against SARS-CoV-2 in rhesus macaques,” Nature, vol. 590(7847); 630-634; Supp'l Data included (2021). [cited by applicant]
McNeilly AS et al., The differential secretion of FSH and LH: regulation through genes, feedback and packaging. Reprod Suppl. 2003;61:463-76. PMID: 14635955. [cited by applicant]
Melanie, P. et al., “Modeling brings additional insights into the kinetics of SARS-CoV-2 neutralizing antibody,” MedRxiv; https://doi.org/10.1101/2021.10.13.21264693; 4 pages (2021). [cited by applicant]
Menzies-Gow, A. et al., “Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma,” N Eng J Med, vol. 384; 1800-1809 (2021). [cited by applicant]
Menzies-Gow, A. et al., “Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?,” Respiratory Research, vol. 21(1); 268; 7 pages (2020). [cited by applicant]
Meyer, M.C. et al., “Development Approach for Anti-Spike Monoclonal Antibodies to Keep Pace with SARS-CoV-2 Variants,” EMA-FDA Workshop: Efficacy of monoclonal antibodies in the context of rapidly evolving SARS-CoV-2 va… [cited by applicant]
Miller, J. et al., “Substantial Neutralization Escape by the SARS-CoV-2 Omicron Variant BQ.1.1,” bioRxiv, https://doi.org/10.1101/2022.11.01.514722; 17 pages (2022). [cited by applicant]
Montgomery, H. et al., “Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (Tackle): a phase 3, randomised, double-blind, placebo-controlled trial,” … [cited by applicant]
Montgomery, H. et al., “Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (Tackle): a phase 3, randomised, double-blind, placebo-controlled trial,” … [cited by applicant]
Moulana A et al., Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA. 1. Nat Commun. Nov. 16, 2022; 13(1):7011. doi: 10.1038/s41467-022-34506-z. PMID: 36384919; PMCID: PMC9668218. [cited by applicant]
Muñoz-Fontela C et al., Advances and gaps in SARS-CoV-2 infection models. PLoS Pathog. Jan. 13, 2022;18(1):e1010161. doi: 10.1371/journal.ppat.1010161. PMID: 35025969; PMCID: PMC8757994. [cited by applicant]
Nader A et al., Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers. Clin Pharmacokinet.… [cited by applicant]
Naldini L et al., Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. Oct. 15, 1996;93(21):11382-8. doi: … [cited by applicant]
Narkhede, Y.B. et al., “Targeting Viral Surface Proteins through Structure-Based Design,” Viruses, vol. 13; 1320; 18 pages (2021). [cited by applicant]
Needleman, S.B. and Wunsch, C.D., “A General Method Applicable to the Search of Similarities in the Amino Acid Sequence of Two Proteins,” J. Mol. Biol., vol. 48; 443-453 (1970). [cited by applicant]
Nicol L et al., Differential secretion of gonadotrophins: investigation of the role of secretogranin II and chromogranin A in the release of LH and FSH in LbetaT2 cells. J Mol Endocrinol. Apr. 2004;32(2):467-80. doi: 10… [cited by applicant]
NIH COVID-19 Treatment Guidelines: Anti-SARS-CoV-2 Monoclonal Antibodies: http://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies (date unavailable… [cited by applicant]
O'Brien, M.P. et al., “Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19,” The New England Journal of Medicine, vol. 385(13); 1184-1195 (2021). [cited by applicant]
Ozawa, H. et al., “The Granin Family—Its Role in Sorting and Secretory Granule Formation,” Cell Structure and Function, vol. 20; 415-420 (1995). [cited by applicant]
Pantaleo, G. et al., “Antibodies to combat viral infections: development strategies and progress,” Nat Rev Drug Discov., Sep. 2022;21(9):676-696. doi: 10.1038/s41573-022-00495-3. Epub Jun. 20, 2022. PMID: 35725925; PMCI… [cited by applicant]
Park, Y. et al., “Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry,” Science, 10.1126/science.abm8143; 14 pages (2022). [cited by applicant]
Park, Y. et al., “Imprinted antibody responses against SARS-CoV-2 Omicron sublineages,” bioRxiv, 68 pages (2022). [cited by applicant]
Pearson, W.R. and Lipman, D.J., “Improved tools for biological sequence comparison,” Proc. Natl. Acad. Sci., vol. 85; 2444-2448 (1988). [cited by applicant]
Perez, J.L., “Use of neutralizing antibody or PK/IC50 threshold to expedite clinical development for prophylactic monoclonal antibodies,” EMA/FDA workshop on monoclonal antibodies against SARS-CoV-2, AstraZeneca, Vaccin… [cited by applicant]
Pérez-Vargas J et al., Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics. Antiviral Res. Jan. 2023;209:105484. doi: 10.1016/j.antiviral.2022.105484. Epub Dec. 8, 2022. Erratum in: Antiviral R… [cited by applicant]
Petkova SB et al., Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. Dec. 2006; 18(12):1759-… [cited by applicant]
Pinto et al. “Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody”, Nature 583(7815): 290-95 (2020). [cited by applicant]
Pinto, D. et al., “Broad betacoronavirus neutralization by a stem helix-specific human antibody,” Science, Supplemental Materials, 37 pages (2021). [cited by applicant]
Pinto, D., et al., “Broad betacoronavirus neutralization by a stem helix-specific human antibody”, Coronavirus, vol. 373, No. 6559, Sep. 3, 2021, pp. 1109-1116. [cited by applicant]
Polack, F.P. et al., “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,” N. Engl. J. Med, vol. 383; No. 27; 2603-2615 (2020). [cited by applicant]
Portal-Celhay, C. et al., “Phase 2 dose-ranging study of the virologic efficacy and safety of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient setting,” medRxiv; https://doi.org/10.1101/20… [cited by applicant]
Pradhan, A. et al., “Affinity maturation of cross-reactive CR3022 antibody against the receptor binding domain of SARS-CoV-2 via in silico site-directed mutagenesis,” Retrieved from Internet URL: http://assets.researchs… [cited by applicant]
Prévost J et al., Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Rep Med. Oct. 20, 2020;1(7):100126. doi: 10.1016/j.xcrm.2020.100126. Epub Sep. 30, 2020. PMID: 33015650; PMCID: PMC7524645. [cited by applicant]
Pymm, P. et al., “Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice,” PNAS, vol. 118; No. 19; e2101918118, 12 pages (2021). [cited by applicant]
Quanterix, The Science of Precision Health, “Simoa® SARS CoV-2 N Protein Advantage Kit: HD-X Data Sheet,” Quanterix Corporation, Doc Template-0061 03; DS-0528 01DS-0528; 2 pages (2020). [cited by applicant]
Quanterix, The Science of Precision Health, “Simoa® SARS-CoV-2 Spike IgG Advantage Kit: HD-X Data Sheet,” Quanterix Corporation, Doc Template-0061 03; DS-0521 01DS-0521; 3 pages (2020). [cited by applicant]
Rambaut, A. et al., “A dynamic nomenclature proposal for SARSCoV-2 lineages to assist genomic epidemiology,” Nat Microbiol., vol. 5; No. 11; 1403-1407 (2020). [cited by applicant]
Chen, J. et al., “Review of COVID-19 Antibody Therapies,” Cornell University Library, New York, 30 pages (2020). [cited by applicant]
Ju, B. et al., “Potent human neutralizing antibodies elicited by SARS-CoV-2 infection,” retrieved from Internet URL: http://www.biorxiv.org/content/10.1101/2020.03.21.990770V2.full.pdf; 42 Pages; Retrieved on Oct. 6, 20… [cited by applicant]
Magar, R. et al., “Potential Neutralizing Antibodies Discovered for Novel Corona Virus Using Machine Learning,” Cornell University Library, New York, 35 pages (2020). [cited by applicant]
Park, T. et al., “Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2” retrieved from Internet URL: http://www.biorxiv.org/content/10.1101/2020.02.22.951178v1.full.pdf; 22 Pages; Retrieved on Jun… [cited by applicant]
Pinto, D. et al., “Structural and functional analysis of a potent sarbecovirus neutralizing antibody,” retrieved from Internet URL: http://www.biorxiv.org/content/10.1101/2020.04.07.023903v3.full.pdf; 28 pages (2020). [cited by applicant]
Planas, D. et al., “Reduced sensitivity of SARA-CoV-2 variant Delta to antibody neutralization,” Nature, 22 pages (2021). [cited by applicant]
Notification of Transmittal of the International Search Report and the Written Opinion for International Application No. PCT/US2021/040533, mailed Oct. 22, 2021. [cited by applicant]
Walser, M. et al., Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates, bioRxiv, 39 pages (2020). [cited by applicant]
Wang, C. et al., “A human monoclonal antibody blocking SARS-CoV-2 infection,” bioRxiv, 24 pages (2020). [cited by applicant]
Wang, C. et al., “A human monoclonal antibody blocking SARS-CoV-2 infection,” Nature Communications, vol. 11; 2251; 6 pages (2020). [cited by applicant]
Wang, E.Y. et al., “Diverse functional autoantibodies in patients with COVID-19,” Nature, Jul. 2021; 595(7866):283-288. doi: 10.1038/s41586-021-03631-y. Epub May 19, 2021. PMID: 34010947. [cited by applicant]
Wang, N. et al., “Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses,” Frontiers in Microbiology, vol. 11; Article 298, 19 pages (2020). [cited by applicant]
Wang, Q. et al., Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants Cell, vol. 186; 279-286 (2023). [cited by applicant]
Wang, Z. et al., “Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins,” Immunity, vol. 55; 1-15, 24 pages (2022). [cited by applicant]
Wang, Z. et al., “Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins,” Immunity, vol. 55; 1-15, 24 pages; Supplemental Information (2022). [cited by applicant]
Weinreich DM et al., REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, N Engl J Med. 384(3):238-251 (2021). [cited by applicant]
Westendorf, K. et al., “LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants,” Cell Rep., vol. 39; No. 7; 110812; 72 Pages (2022). [cited by applicant]
WHO website. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Updated Feb. 17, 2023. Accessed Feb. 19, 2023. https://covid19.who.int/. [cited by applicant]
Worzner, K. et al., “Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice,” EBioMedicine, vol. 63; 103197; 9 pages (2021). [cited by applicant]
Wrapp, D. et al., “Crystal structure of the SARS-CoV-1 RBD bound by the cross-reactive single-domain antibody SARS VHH-72,” Protein Data Bank (PDB) Accession No. 6WAQ, retrieved from Internet URL: https://www.rcsb.org/s… [cited by applicant]
Wrapp, D. et al., “Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Doman Camelid Antibodies,” Cell, vol. 181; 1004-1015 (2020). [cited by applicant]
Wrapp, D., et al., “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation”, Science, vol. 367, No. 6483, Feb. 19, 2020, pp. 1260-1263. [cited by applicant]
Wu H et al., Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. May 4, 2007;368(3):652-65. doi: 10.1016… [cited by applicant]
Wu, Y. et al., “A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2,” Science, vol. 368; 1274-1278 (2020). [cited by applicant]
Wu, Y. et al., “Identification of Human Single-Domain Antibodies against SARS-CoV-2,” Cell Host & Microbe, vol. 27; 891-898 (2020). [cited by applicant]
Xiang, Y. et al., Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2, bioRxiv, Retrieved from Internet URL: https://www.biorxiv.org/content/10.1101.2020.08.24.264333v3.full.pdf; 34 Pages (2020). [cited by applicant]
Xu, J. et al., “Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants,” Nature, vol. 595; 278-282 (2021). [cited by applicant]
Yamin R et al., Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature. Nov. 2021;599(7885):465-470. doi: 10.1038/s41586-021-04017-w. Epub Sep. 21, 2021. PMID: 34547765; PMCID: PMC9038156. [cited by applicant]
Yang, D. et al., “Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics,” Analytical Biochemistry, vol. 508; 78-96 (2016). [cited by applicant]
Yonesi, M. and Rezazadeh, A., “Plants as a prospective source of natural anti-viral compounds and oral vaccines against COVID-19 coronavirus,” preprint, https://doi.org/10.20944/preprints202004.0321.v1; 31 pages (2020). [cited by applicant]
Yoshinaga et al., “Ig L-chain Shuffling for Affinity Maturation of Phage Library-derived Human Anti-human MCP-1 Antibody Blocking its Chemotactic Activity” J. Biochem; 143:593-601 (2008). [cited by applicant]
Young, S. and Linville-Engler, G., “INVIVYD Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222FOR the Pre-Exposure Prevention of COVID-19 in Immunocompromised Adults Andadolescents,” Retrieved … [cited by applicant]
Yuan M et al., A broad and potent neutralization epitope in SARS-related coronaviruses. Proc Natl Acad Sci U S A. Jul. 19, 2022;119(29):e2205784119. doi: 10.1073/pnas.2205784119. Epub Jun. 29, 2022. PMID: 35767670; PMCI… [cited by applicant]
Yuan, M. et al., “A higly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV,” Science, vol. 368; 4 pages (2020). [cited by applicant]
Zalevsky, J. et al., “Enhanced antibody half-life improves in vivo activity,” Nat. Biotechnol., vol. 28; No. 2; 157-159 (2010). [cited by applicant]
Zhang A et al., Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat Rev Immunol. Jun. 2023;23(6):381-396. doi: 10.1038/s41577-022-00813-1. Epub Dec. 19, 2022. PMID: 36536068; PMC… [cited by applicant]
Zhang, F. et al., “Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents,” bioRxiv; https://doi.org/10.1101/2022.08.24.505169; 47 pages (2022). [cited by applicant]
Zhang, H. et al., “Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity,” Nature, https://doi.org/10.1038/s41586-023-06127-z, 52 pages (2023). [cited by applicant]
Zhao, E. et al., “The Secretogranin II-Derived Peptide Secretoneurin Stimulates Luteinizing Hormone Secretion from Gonadotrophs,” Endocrinology, vol. 150; No. 5; 2273-2282 (2009). [cited by applicant]
Zhao, F. et al., “Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution,” Retrieved from Internet URL: http://biorxiv.org/content/10.1101.2021.05.29.443900v1.full.… [cited by applicant]
Zhou et al. “A general-purpose protein design framework based on mining sequence-structure relationships in known protein structures”, Proc Natl Acad Sci U S A. 117(2):1059-68 (2020). [cited by applicant]
Zhou, D. et al., “Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera,” Cell, vol. 184(9); 2348-2361 (2021). [cited by applicant]
Zhou, P., et al., “A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection”, Science Translational Medicine, vol. 14, No. 637, Mar. 23, 2022, 2 pa… [cited by applicant]
Zhou, Q., “Considerations Regarding Assessment of A Modified Monoclonal Antibody (mAb) Product Related to A Prototype mAb Product in Addressing Emerging SARS-COV-2 Variants—A CMC Perspective,” Presentation; EMA-FDA Work… [cited by applicant]
Ziegler, C.G.K. et al., “SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets Across Tissues,” Cell, vol. 181; 1016-1035 (2020). [cited by applicant]
Zost SJ et al., Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. Aug. 2020;584(7821):443-449. doi: 10.1038/s41586-020-2548-6. Epub Jul. 15, 2020. PMID: 32668443; PMCID: PMC7584396. [cited by applicant]
Zupancic, J.M. et al., “Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS-CoV-2,” Advanced Therapeutics, vol. 4; 2100099; 9 Pages (2021). [cited by applicant]
Rappazzo CG et al., Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. Feb. 19, 2021;371(6531):823-829. doi: 10.1126/science.abf4830. Epub Jan. 25, 2021. PMID: 33495… [cited by applicant]
Rockett, R. et al., “Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use,” N Engl J Med, vol. 386; No. 15; 4 pages (2022). [cited by applicant]
Rudikoff et al. “Single amino acid substitution altering antigen-binding specificity”, Proceedings of the National Academy of Sciences, National Academy of Sciences, vol. 79, Mar. 1, 1982 (Mar. 1, 1982), p. 1979-1983, X… [cited by applicant]
Rujas, E. et al., “Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers,” Nature Communications, vol. 12(1); 3661; 12 pages (2021). [cited by applicant]
Sauer, M. M., et al., “Structural basis for broad coronavirus neutralization”, Nature Structural & Molecular Biology, vol. 28, 2021, pp. 478-486. [cited by applicant]
Saunders, K.O., “Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life,” Front Immunol., vol. 10; 1296 (2019). [cited by applicant]
Saunders, K.O., “Developing a Neutralizing Antibody Vaccine for Pandemic and Pre-Emergent Coronaviruses,” Duke University School of Medicine, IDWeek, 31 pages (2023). [cited by applicant]
Schepens, B. et al., “An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models,” Sci Transl Med., vol. 13; eabi7826; 18 pages (2021). [cited by applicant]
Schoof, M. et al., “An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation,” bioRxiv, Retrieved from Internet URL: https://www.biorxiv.org/content/10.1101.2020.08.08.238… [cited by applicant]
Service, R.F., “New antibodies that the coronavirus can't elude,” Science, vol. 380; Issue 6647; 779-780 (2023). [cited by applicant]
Seydoux E et al., Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity. Jul. 14, 2020;53(1):98-105.e5. doi: 10.1016/j.immuni.2020.06.… [cited by applicant]
Sheridan, D. et al., “Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extneded duration of action,” PLoS One, vol. 13; No. 4; e0195909; 15 pages (2018). [cited by applicant]
Sherman, A.C. et al., “The Future of Flu: A Review of the Human Challenge Model and Systems Biology fort Advancement of Influenza Vaccinology,” Frontiers in Cellular and Infection Microbiology, vol. 9; Article 107; 9 pa… [cited by applicant]
Sheward, D.J. et al., “Structural basis of Omicron neutralization by affinity-matured public antibodies,” bioRxiv, 24 pages (2022). [cited by applicant]
Shi, R. et al., “A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2,” Nature, vol. 584; No. 7819; 120-124 (2020). [cited by applicant]
Sia, S.F. et al., “Pathogenesis and transmission of SARS-CoV-2 in golden hamsters,” Nature, vol. 583; 834-837; Supp'l Data included (2020). [cited by applicant]
Smith, T.F. and Waterman, M.S., “Comparison of Biosequences,” Advances in Applied Mathematics, vol. 2; 482-489 (1981). [cited by applicant]
Snijder J et al., An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. Immunity. Apr. 17, 2018;48(4):799-811.e9. doi: 10.1016/j.immuni.2… [cited by applicant]
Song et al. “Cytokine storm induced by SARS-CoV-2”, Clin Chim Acta. 509:280-7 (2020). [cited by applicant]
Song, Y. et al., “Effects of Secretoneurin and Gonadotropin-Releasing Hormone Agonist on the Spawning of Captive Greater Amberjack ( [cited by applicant]
Stadler, E. et al., “Determinants of passive antibody effectiveness in SARS-CoV-2 infection,” medRxiv; https://doi.org/10.1101/2022.03.21.22272672; 28 pages (2022). [cited by applicant]
Stadler, E. et al., “Monoclonal antibody levels and protection from COVID-19,” medRxiv; https://doi.org/10.1101/2022.11.22.22282199; 26 pages (2022). [cited by applicant]
Stamatatos L et al., mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. Mar. 25, 2021;372(6549):1413-8. doi: 10.1126/science.abg9175. Epub ahead of print. PMID: 3376… [cited by applicant]
Starr, T.N. et al., “SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape,” Nature, https://doi.org/10.1038/s41586-021-03807-6; 36 pages (2021). [cited by applicant]
Stryer, L., Biochemistry, 4th edition, W. H. Freeman and Company, 1995, pp. 18-23. [cited by applicant]
Sun, B., “Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2,” Nature Portfolio, Nature Microbiology, Reviewer comments & Editors Decisions, 55 pages, No Date Given. [cited by applicant]
Sun, D. et al., “Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes,” Nature Communications, vol. 12; 4676; 14 pages (2021). [cited by applicant]
Sun, X. et al., “Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2,” Nature Microbiology, vol. 7; 1063-1074 (2022). [cited by applicant]
Sun, X. et al., “Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2,” Nature Microbiology, vol. 7; 1063-1074; Supplemental Data (2022). [cited by applicant]
Tabynov, K. et al., “An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission,” npj Vaccines, vol. 7; No. 24; 10 pages (2022). [cited by applicant]
Tao, K. et al., “The biological and clinical significance of emerging SARS-CoV-2 variants,” Nature Reviews Genet., vol. 22; 757-773 (2021). [cited by applicant]
Ter Meulen J et al., Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet. Jun. 26, 2004;363(9427):2139-41. doi: 10.1016/S0140-6736(04)16506-9. PMID: 15220038; PMCID: PMC7112500. [cited by applicant]
Ter Meulen, J. et al., “Human Monoclonal Antibody Combination against SARA Coronavirus: Synergy and Coverage of Escape Mutants,” PloS; vol. 3; Issue 7; e237; 9 pages (2006). [cited by applicant]
Tian, X. et al., “Potent binding of 2019 novel coronavirus spike protein by a SARA coronavirus-specific human monoclonal antibody,” Emerging Microbes & Infections, vol. 9; 4 pages (2020). [cited by applicant]
Tortorici et al. “Broad sarbecovirus neutralization by a human monoclonal antibody”, Nature. Sep. 2021;597 (7874):103-108. doi: 10.1038/s41586-021-03817-4. Epub Jul. 19, 2021 PMID: 34280951. [cited by applicant]
Tortorici et al. “Broad sarbecovirus neutralization by a human monoclonal antibody”, Nature. Sep. 2021;597 (7874):103-108. doi: 10.1038/s41586-021-03817-4. Epub Jul. 19, 2021 PMID: 34280951; Suppl. info. [cited by applicant]
Tortorici, M.A. et al., “Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms,” Science, vol. 370; 950-957 (2020). [cited by applicant]
Trudeau VL et al., Is secretoneurin a new hormone? Gen Comp Endocrinol. Jan. 1, 2012;175(1):10-8. doi: 10.1016/j.ygcen.2011.10.008. Epub Oct. 20, 2011. PMID: 22036841. [cited by applicant]
Turelli, P. et al., “P2G3 human monoclonal antibody neutralizes SARS-CoV-2 Omicron subvariants including BA.4 and BA.5 and Bebtelovimab escape mutants,” bioRxiv, 15 pages (2022). [cited by applicant]
U.S. Department of Health and Human Services, “COVID-19: Developing Drugs and Biological Products for Treatment or Prevention Guidance for Industry,” Center for Drug Evaluation and Research (CDER); Center for Biologics … [cited by applicant]
U.S. Department of Health and Human Services, “Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization Guidance for Industry,” Center for Drug Evaluation and Research (CDER); 14 … [cited by applicant]
Ullah, I. et al., “Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy,” Immunity, vol. 54; 2143-2158 (2021). [cited by applicant]
Ullah, I. et al., “Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy,” Immunity, vol. 54; 2143-2158; Supplemental Information (2021). [cited by applicant]
Vajdos et al. (J Mol Biol. Jul. 5, 2002; 320(2):415-28). (Year: 2002). [cited by applicant]
Van Egerens, D. et al., “Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein,” medRxiv, https://doi.org/10.1101/2020.11.17.20233726; 28 pages (2020). [cited by applicant]
Veesler, D. et al., “SARS-CoV-2 S glycoprotein in complex with S2X259 Fab,” Worldwide Protein Data Bank, Full wwPDB EM Validation Report; EMDB ID: EMD-24347, PDB ID: 7RA8; 76 pages (2022). [cited by applicant]
Verstraete, K. et al., “Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma,” Nature Communications, vol. 8; 14937; 17 pages (2017). [cited by applicant]
Vir Biotechnology, “Vir Biotechnology Announces Topline Data from Phase 2 Peninsula Trial Evaluating VIR-2482 for thePrevention of Seasonal Infl uenza A Illness,” Retrieved from Internet URLhttps://investors.vir.bio/new… [cited by applicant]
Walker KW et al., Pharmacokinetic comparison of a diverse panel of non-targeting human antibodies as matched IgG1 and IgG2 isotypes in rodents and non-human primates. PLoS One. May 23, 2019;14(5):e0217061. doi: 10.1371/… [cited by applicant]
Walker, L.M. and Burton, D.R., “Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray,” Nature Reviews, vol. 18; 297-308 (2018). [cited by applicant]
Haagmans, B.L. et al., “SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model,” Journal of Infectious Diseases, vol. 223(12):2020-2028 (2021). [cited by applicant]
Hansen, J. et al., “Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail,” Science, vol. 369(6506); 1010-1014 (2020). [cited by applicant]
Haraya, K. et al., “Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations,” BioDrugs, vol. 37; No. 1; 99-108 (2023). [cited by applicant]
Harpaz R. et al., “Prevalence of Immunosuppression Among US Adults, 2013,” JAMA, vol. 316; No. 23; 2547-2548 (2016). [cited by applicant]
Hastie, K.M. et al., “Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study,” Science, 10.1126/science.abh2315; 13 pages (2021). [cited by applicant]
Hastie, K.M. et al., “Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study,” Science, 10.1126/science.abh2315; 13 pages; Supplemental Information (2021). [cited by applicant]
Hie, B.L. et al., “Efficient evolution of human antibodies from general protein language models,” Nature Biotechnology, https://doi.org/10.1038/s41587-023-01763-2; 26 pages (2023). [cited by applicant]
Highlights of Emergency Use Authorization, Bebtelovimab, 21 pages (2022). [cited by applicant]
Highlights of Emergency Use Authorization, Evusheld, 27 pages (2021). [cited by applicant]
Highlights of Emergency Use Authorization, Evusheld; 30 pages; Revised Jan. 2023. [cited by applicant]
Hirsch C. et al., “SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19,” Cochrane Database Syst Rev., Issue 6; Art No. CD014945; 106 pages (2022). [cited by applicant]
Hirsch C. et al., “SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19,” Cochrane Database Syst Rev., vol. 6; Issue 6; Art No. CD014945; 89 pages (2022). [cited by applicant]
Holland et al., ACTIV-3—Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir… [cited by applicant]
Hu, D. and Irving, A. T., “Massively-multiplexed epitope mapping techniques for viral antigen discovery,” Front. Immunol., vol. 14; 1192385; 13 pages (2023). [cited by applicant]
Hua L et al., MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a [cited by applicant]
Huang, Y. et al., “Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses,” bioRxiv, 27 (2021). [cited by applicant]
Huang, Y. et al., “Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses,” bioRxiv, 27; Supplemental Information (2021). [cited by applicant]
Huo, J. et al., “Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2,” Nature Structural and Molecular Biology, vol. 27; 846-854 (2020). [cited by applicant]
Hurlburt N.K. et al., “Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit,” Commun Biol., vol. 5; No. 1; 342; 13 Pages (2022). [cited by applicant]
Ingraham et al. “Generative models for graph-based protein design”, 33rd Conference on Neural Information Processing Systems (Neurl PS 2019), Vancouver, Canada. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/040533, mailed on Jan. 19, 2023, 9 pages. [cited by applicant]
Irvin SC et al., REGEN-COV® antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification. Bioanalysis. Dec. 2021;13(24):1827-1836. doi: 10.4155/bio-2021-0190. Epub No… [cited by applicant]
Isa F et al., Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19. Int J Infect Dis. Sep. 2022;122:585-592. doi: 10.1016/j.ijid.2022.06.045… [cited by applicant]
Ishino, T. et al., “Engineering a Monomeric Fc Domain Modality by N-Glycosylation for the Half-life Extension of Biotherapeutics,” Journal of Biological Chemistry, vol. 288; No. 23; 16529-16537 (2013). [cited by applicant]
Janeway et al., The Recognition of Antigen, Immunobiology, 3rd edition, Garland Publishing Inc., 1997, pp. 3:1-3:11. [cited by applicant]
Jennewein M.F. et al., “Isolation and characterization of crossneutralizing coronavirus antibodies from COVID-19+ subjects,” Cell Rep. vol. 36; No. 2; 109353; 22 Pages (2021). [cited by applicant]
Jette, C.A. et al., “Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies,” Cell Reports, vol. 36; 109760; 23 pages (2021). [cited by applicant]
Jiang, N. et al., “Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omnicron lineage variants,” bioRxiv; 21 pages (2023). [cited by applicant]
Jiang, W. et al., “Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV,” MABS, vol. 13; No. 1; e1953683; 12 pages (2021). [cited by applicant]
Jones, B.E. et al., “The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates,” Sci. Transl. Med., vol. 13; eabf1906; 17 pages (2021). [cited by applicant]
JP Morgan Healthcare Conference, Regeneron; Retrieved from Internet URL: https://investor.regeneron.com/events/event-details/41st-annual-jp-morgan-healthcare-conference; 37 pages; Retrieved on Jan. 29, 2024. [cited by applicant]
Kaku Y et al., Virological characteristics of the SARS-CoV-2 JN. 1 variant. Lancet Infect Dis. Feb. 2024;24(2):e82. doi: 10.1016/S1473-3099(23)00813-7. Epub Jan. 3, 2024. PMID: 38184005. [cited by applicant]
KC, B.B. et al., “A machine learning platform to estimate anti-SARS-CoV-2 activities,” Nature Machine Intelligence, https://doi.org/10.1038/s42256-021-00335-w; 9 pages (2021). [cited by applicant]
Khoury DS et al., Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. Jul. 2021;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub May 17, 2021. PM… [cited by applicant]
Killingley, B. et al., “Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults,” Nature Medicine, vol. 28, 1031-1041 (2022). [cited by applicant]
Knierman, M.D. et al., “The Human Leukocyte Antigen Class II Immunopeptidome of the SARS-CoV-2 Spike Glycoprotein,” Cell Reports, vol. 33; 1 08454; 15 pages (2020). [cited by applicant]
Kreuzberger N. et al., “SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19,” Cochrane Database Syst Rev, vol. 9; No. 9 229 pages (2021). [cited by applicant]
Kunik, V. et al., “Paratome: an online tool for systematic identification of antigen-binding regions in antibodies based on sequence or structure,” Nucleic Acids Research, vol. 40; W521-W524 (2012). [cited by applicant]
Kupferschmidt, K., “Evolving threat,” Science, vol. 373; No. 6557; 844-849 (2021). [cited by applicant]
Kurasaki, H. et al., “Safety and Pharmacokinetics of PA-001, a New Potential COVID-19 Drug That Targets the S2 Subunit of SARS-CoV-2 Spike Protein, in Healthy Subjects,” Poster Abstracts; Abstract citation ID: ofad500.2… [cited by applicant]
Kurhade C et al., Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. Feb. 2023;29(2):344-347. Safety and efficacy of inhaled IBIO123 for se… [cited by applicant]
Ladde, S.M. et al., “Safety and efficacy of inhaled IBIO123 for severe COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial,” The Lancet, 35 pages (2023). [cited by applicant]
Ladner, J. T., et al., “Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses”, Cell Reports Medicine, vol. 2 No. 1, Jan. 1, 2021, 18 pages. [cited by applicant]
Laracy JC et al., Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside. Curr Opin Infect Dis. Aug. 1, 2022;35(4):271-279. doi: 10.1097/QCO.0000000000000841. Epub Jul. 5, 2022. PM… [cited by applicant]
Leach, M.W. et al., “Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions,” Toxicol Pathol, vol. 38; No. 7; 1138-1166 (2… [cited by applicant]
Levin EG et al., Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. Dec. 9, 2021;385(24):e84. doi: 10.1056/NEJMoa2114583. Epub Oct. 6, 2021. PMID: 34614326; PMCID: PMC8522797. [cited by applicant]
Levin M.J. et al., “Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19,” N. Engl. J. Med., vol. 386; No. 23; 2188-2200 (2022). [cited by applicant]
Levin M.J. et al., “Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19,” N. Engl. J. Med., vol. 386; No. 23; 2188-2200; The Protocol; 424 pages (2022). [cited by applicant]
Levin, M.J. et al., “AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019,” Clinical Infectious Diseases, vol. 76; No. 7; 1247-1256 (2023). [cited by applicant]
Li W. et al., “Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern,” Cell Rep., vol. 38; No. 2; 110210; 28 pages (2022). [cited by applicant]
Gubbins et al., “Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus”, Molecular Immunology, vol. 42, No. 1, 2005, pp. 125-136. [cited by applicant]